Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | BRS3 | P32247 | 10/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12795970 | 0.89 | OPRK1 (0.45) | JAK2JAK1JAK3HRH4BRS3 | |
| SCHEMBL541600 | 0.88 | KDR (0.45) | JAK2JAK1JAK3HRH4BRS3 | |
| SCHEMBL541601 | 0.88 | KDR (0.45) | JAK2JAK1JAK3HRH4BRS3 | |
| SCHEMBL12796040 | 0.84 | JAK2 (0.42) | JAK2JAK1JAK3HRH4BRS3 | |
| SCHEMBL12796029 | 0.84 | JAK2 (0.42) | JAK2JAK1JAK3HRH4BRS3 | |
| SCHEMBL542036 | 0.82 | HSD11B1 (0.43) | JAK2JAK1JAK3HRH4KDR | |
| SCHEMBL542035 | 0.82 | HSD11B1 (0.43) | JAK2JAK1JAK3HRH4KDR | |
| SCHEMBL541876 | 0.82 | HRH4 (0.42) | JAK2JAK1JAK3HRH4BRS3 | |
| SCHEMBL541877 | 0.82 | HRH4 (0.42) | JAK2JAK1JAK3HRH4BRS3 | |
| SCHEMBL541878 | 0.82 | HRH4 (0.42) | JAK2JAK1JAK3HRH4BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | JAK2 575/4885JAK1 1430/4885JAK3 1312/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | JAK2 265/4885JAK1 843/4885JAK3 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.